{"created":"2023-06-19T11:39:55.636655+00:00","id":8160,"links":{},"metadata":{"_buckets":{"deposit":"e1c52ffb-7643-4b1a-8296-68797b086f0b"},"_deposit":{"created_by":15,"id":"8160","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"8160"},"status":"published"},"_oai":{"id":"oai:mie-u.repo.nii.ac.jp:00008160","sets":["631:636:1692684632717"]},"author_link":["20302","20303","20304","20299","20300","20301"],"item_8_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-06-11","bibliographicIssueDateType":"Issued"}}]},"item_8_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"NAKATANI, Kaname","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"20302","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"MOCHIKI, Ikuyo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"20303","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"NOBORI, Tsutomu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"20304","nameIdentifierScheme":"WEKO"}]}]},"item_8_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"ゲノム解析技術の開発速度は著しく、多くの研究室でゲノムを扱えるようになり、多数の研究成果が創出されるようになった。全自動SNP解析装置が次々と開発され医療現場に導入されていった。我々の施設でも導入しPGx検査に活用しているが、単一あるいは少数のSNP解析で臨床に役立つものは、それほど多いわけではない。多数のSNPを解析する有用性も明らかになってきたため、網羅的解析が可能となるマイクロアレイシステムを導入し、PGx検査を用いた2型糖尿病患者の薬剤効果予測の検討を始めた。","subitem_description_type":"Abstract"},{"subitem_description":"Personalized medicine based on pharmacogenomics is being developed at the clinical stage. These developments in personalized medicine are strongly supported by marked innovations in genetic analyses. However, there are currently no potential companion diagnostics for common diseases. As common diseases are multifactorial, we appreciated that drugs pass through complex metabolic pathways was important rather than experience a single enzymatic modification to predict therapeutic efficacy. We attempted DNA microarray system in type 2 diabetes mellitus (T2DM). Sitagliptin is most popular DPP4-i, but showed individual response variability. We designed a study to develop personalized medicine of T2DM by sitagliptin based on drug metabolism. Sitagliptin is excreted through kidney and pharmacokinetics is mostly regulated by P-glycoprotein (ABCB1) and organic anion transport (OAT3). We analyzed multiple genetic variants determined by the DMET including ABCB1 and OAT3 in T2DM patients.","subitem_description_type":"Abstract"}]},"item_8_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"2012年度～2014年度科学研究費補助金(基盤研究(C))研究成果報告書","subitem_description_type":"Other"}]},"item_8_description_64":{"attribute_name":"科研費番号","attribute_value_mlt":[{"subitem_description":"24590693","subitem_description_type":"Other"}]},"item_8_publisher_30":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"三重大学"}]},"item_8_text_18":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_text_value":"Pharmacogenomics using DNA Microarray in the treatment of type 2 diabetes"}]},"item_8_text_65":{"attribute_name":"資源タイプ（三重大）","attribute_value_mlt":[{"subitem_text_value":"Kaken / 科研費報告書"}]},"item_8_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"中谷, 中","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"20299","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"望木, 郁代","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"20300","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"登, 勉","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"20301","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-02-18"}],"displaytype":"detail","filename":"39K17867.pdf","filesize":[{"value":"372.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"39K17867.pdf","url":"https://mie-u.repo.nii.ac.jp/record/8160/files/39K17867.pdf"},"version_id":"c6f5ebf2-546d-4278-93e6-f68a9c54da53"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"ファーマコゲノミクス","subitem_subject_scheme":"Other"},{"subitem_subject":"2型糖尿病","subitem_subject_scheme":"Other"},{"subitem_subject":"薬剤トランスポーター","subitem_subject_scheme":"Other"},{"subitem_subject":"DNAマイクロアレイ","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"糖尿病薬併用療法におけるファーマコゲノミクス検査の有用性の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"糖尿病薬併用療法におけるファーマコゲノミクス検査の有用性の検討","subitem_title_language":"ja"}]},"item_type_id":"8","owner":"15","path":["1692684632717"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2017-01-13"},"publish_date":"2017-01-13","publish_status":"0","recid":"8160","relation_version_is_last":true,"title":["糖尿病薬併用療法におけるファーマコゲノミクス検査の有用性の検討"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2023-08-30T06:21:46.973330+00:00"}